Vistagen Therapeutics, Inc. has reported its financial results for the second quarter of fiscal year 2027, which ended on September 30, 2026. The company, a late clinical-stage biopharmaceutical firm, is focusing on advancing its development plan for fasedienol, a potential treatment for social anxiety disorder. This update is significant as it reflects the company's ongoing commitment to innovation in the pharmaceutical sector.

Vistagen Therapeutics, Inc. operates under the SIC classification of 2834, which pertains to Pharmaceutical Preparations. The company is listed on the Nasdaq under the ticker symbol VTGN. Recent filings include an 8-K on November 13, 2026, detailing their financial results, as well as a 10-Q for the same date, showcasing their operational performance.

In the recent 8-K filing, Vistagen disclosed that on November 13, 2026, it issued a press release announcing its financial results for the second quarter of fiscal year 2027. The press release, attached as Exhibit 99.1, highlights key financial metrics and corporate updates. Notably, the company reported a net loss of $10.7 million for the quarter, a decrease from the $19.4 million loss reported in the same period the previous year.

The filing indicates that research and development (R&D) expenses for the quarter were $6.6 million, significantly lower than the $15.9 million spent in the prior year. This reduction is attributed to the completion of various clinical studies and a decrease in headcount-related expenses. Furthermore, general and administrative (G&A) expenses rose slightly to $4.5 million, primarily due to increased consulting and legal fees.

Vistagen's financial position remains stable, with cash and marketable securities totaling $20 million as of September 30, 2026. The company believes this amount will be sufficient to fund operations into 2027, although it may not extend beyond that timeframe without additional capital.

In terms of corporate strategy, Vistagen is advancing its Phase 3 development plan for fasedienol in social anxiety disorder. Following a recent meeting with the FDA, the company received constructive feedback regarding its clinical study design, including recommendations for using the Liebowitz Social Anxiety Scale as the primary endpoint. This feedback is crucial as it aligns with Vistagen's goal of demonstrating the long-term benefits of fasedienol for patients.

Additionally, the company announced the appointment of Douglas J. Williamson, MD, to its Board of Directors, bringing valuable experience in neuroscience drug development. Vistagen is also implementing cost-management initiatives to prioritize capital allocation across its clinical-stage programs, ensuring a disciplined approach to financial management.

As Vistagen continues to navigate the complexities of drug development and regulatory approval, its focus on innovative treatments positions it well within the competitive pharmaceutical landscape. The company aims to provide safer alternatives for patients suffering from conditions like social anxiety disorder, leveraging its unique intranasal product candidates.

Looking ahead, Vistagen's strategic focus on executing its development plans while maintaining flexibility in capital management will be critical for its success. The company is expected to continue updating stakeholders on its progress as it moves forward with its clinical programs.